In Vivo Gene Editing Market is expected to Hit US$ 37.75 Billion by 2035 | Major Companies - CRISPR Therapeutics, Beam Therapeutics Inc., Prime Medicine, Inc., Verve Therapeutics Inc.

DataM Intelligence has unveiled its latest report on the "In Vivo Gene Editing Market Size 2026" delivering powerful insights into key trends, future growth opportunities, and evolving market challenges. Designed to empower smarter decision-making, the report equips businesses with the strategic intelligence needed to stay ahead in a competitive landscape. By blending robust qualitative analysis with data-driven quantitative research, DataM Intelligence offers a well-rounded perspective that helps organizations decode complex market dynamics, unlock new avenues for growth, and seize emerging opportunities in an ever-evolving global market.

Unlock Strategic Partnerships in the Growing In Vivo Gene Editing Market-Connect with Key Industry Leaders Today: https://www.datamintelligence.com/partner-identification-enquiry/in-vivo-gene-editing-market?sz

The Global In Vivo Gene Editing Market size reached US$ 2.46 billion in 2025 and is expected to reach US$ 37.75 billion by 2035, growing with a CAGR of 34.09% during the forecast period 2026-2035.

The In Vivo Gene Editing Market refers to the industry focused on technologies, therapies, and products that enable direct modification of genetic material within a patient's body to treat or prevent diseases. It includes gene editing platforms, delivery systems, clinical applications, and therapeutic developments targeting genetic disorders, cancer, and rare diseases. Market growth is driven by advancements in precision medicine, increasing investment in biotechnology, expanding clinical trials, and rising demand for personalized treatment approaches.

Download Free Sample Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/in-vivo-gene-editing-market?sz

Recent Industry Developments: United States

✅ April 2026: Intellia Therapeutics reported positive late-stage clinical results for its in vivo CRISPR therapy targeting hereditary angioedema. The therapy achieved major reductions in swelling attacks, strengthening commercialization prospects and accelerating planned U.S. regulatory submissions.

✅ February 2026: The U.S. in vivo gene editing ecosystem saw increasing investment and partnership activity focused on AI-enabled protein engineering and gene delivery platforms to improve editing precision and therapeutic development efficiency.

✅ January 2026: Industry analysts highlighted stronger funding momentum for investigator-sponsored trials and global collaborations in cell and gene therapies, supporting faster clinical validation of in vivo editing approaches and expanding pipeline development in the U.S. market.

Recent Industry Developments: Japan

✅ April 2026: Japan continued expanding genome editing adoption through government-backed precision medicine initiatives and rising investment in therapeutic applications for rare genetic disorders, supporting growth of in vivo editing technologies.

✅ March 2026: Japanese researchers and biotech institutions increased focus on commercialization of in vivo gene editing therapies, supported by clinical trial activity, AI-assisted editing workflows, and regulatory encouragement for personalized medicine.

✅ January 2026: Researchers at the Institute of Medical Science, The University of Tokyo demonstrated CRISPR-Cas3 as a potential alternative to CRISPR-Cas9 for in vivo treatment of transthyretin amyloidosis (ATTR), showing efficient gene deletion with reduced off-target effects in mouse models. The work strengthened Japan's position in next-generation therapeutic genome editing research.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/in-vivo-gene-editing-market?sz

List of the Key Players in the In Vivo Gene Editing Market:

Intellia Therapeutics, Inc.
CRISPR Therapeutics
Beam Therapeutics Inc.
Editas Medicine, Inc.
Prime Medicine, Inc.
Verve Therapeutics Inc.
Sangamo Therapeutics, Inc.
Precision BioSciences
Arbor Biotechnologies
Metagenomi Therapeutics, Inc.
Caribou Biosciences, Inc.
Regeneron Pharmaceuticals Inc.
Wave Life Sciences Ltd.
Korro Bio, Inc.
Mammoth Biosciences
Scribe Therapeutics

How Does Market Research Work in the In Vivo Gene Editing Market?

Market research for the In Vivo Gene Editing Market involves systematic data collection and analysis to understand industry trends, customer behavior, and competitive dynamics. It includes primary research such as surveys and interviews, and secondary research from reports, databases, and publications. Analysts evaluate market size, growth drivers, challenges, and opportunities using qualitative and quantitative methods. Insights are validated through expert opinions and forecasting models, enabling businesses to make strategic decisions, identify target segments, and gain a competitive advantage in a rapidly evolving market.

Latest Mergers and Acquisitions of In Vivo Gene Editing Market:

✅ April 2026: Eli Lilly acquires Kelonia Therapeutics (up to US$ 7 Billion)
➠ Acquirer: Eli Lilly and Company
➠ Target: Kelonia Therapeutics
➠ Deal Value: Up to US$ 7 billion (US$ 3.25 billion upfront + milestones)
➠ Why it Matters: Kelonia develops in vivo CAR-T and genetic medicines, enabling immune cells to be engineered directly inside the patient's body. The acquisition strengthens Lilly's position in next-generation in vivo gene-editing and oncology therapies.

✅ February 2026: Eli Lilly acquires Orna Therapeutics (up to US$ 2.4 Billion)
➠ Acquirer: Eli Lilly and Company
➠ Target: Orna Therapeutics
➠ Deal Value: Up to US$ 2.4 billion
➠ Why it Matters: Orna's platform allows therapies to be generated inside the body (in vivo) without removing patient cells, supporting advanced genetic medicine and cell engineering applications. The acquisition expands Lilly's in vivo therapeutic pipeline.

✅ January 2026: Eli Lilly-Seamless Therapeutics Strategic Acquisition/Platform
➠ Deal (up to US$ 1.12 Billion)
➠ Companies: Eli Lilly and Company & Seamless Therapeutics
➠ Deal Value: Up to US$ 1.12 billion
➠ Type: Major platform partnership with commercialization rights (often tracked alongside gene-editing M&A activity)
➠ Why it Matters: Lilly gained access to programmable recombinase gene-editing technology capable of making large, precise DNA modifications for genetic disease treatment, including future in vivo applications.

Segments Covered in the In Vivo Gene Editing Market 2026:

By Editing Technology: CRISPR, Base Editing, Prime Editing, TALEN, ZFN, RNA Editing, Epigenome Editing, Others.

By Delivery Platform: Viral Vectors, Non Viral Delivery, Virus Like Particles, Others.

By Payload Type: DNA, RNA, Protein, Ribonucleoprotein Complexes.

By Route of Administration: Intravenous, Intrathecal, Intravitreal, Intramuscular, Subcutaneous, Intratumoral, Inhalation, Local Injection.

By Target Organ: Liver, Eye, Central Nervous System, Blood and Bone Marrow, Muscle, Lung, Heart, Kidney, Skin, Others.

By Application: Rare Genetic Disorders, Hematological Disorders, Cardiometabolic and Liver Disorders, Oncology, Neurological Disorders, Ophthalmic Disorders, Infectious Diseases, Musculoskeletal Disorders, Others.

By Editing Outcome: Gene Knockout, Gene Correction, Gene Insertion, Gene Silencing, Gene Activation.

By Development Stage: Discovery, Preclinical, Phase I, Phase II, Phase III, Commercial.

By End User: Biotechnology Companies, Pharmaceutical Companies, CDMOs, Academic and Research Institutes, Contract Research Organizations, Hospitals and Specialty Centers.

Regional Analysis of the In Vivo Gene Editing Market:

⇥ North America: Leads the market due to advanced infrastructure, strong R&D investments, and early adoption of new technologies.

⇥ Europe: Shows steady growth supported by strict regulations and increasing focus on sustainability initiatives.

⇥ Asia-Pacific: Fastest-growing region driven by rapid industrialization, urbanization, and rising consumer demand in emerging economies.

⇥ Latin America: Experiences moderate growth with expansion in industrial and commercial sectors.

⇥ Middle East & Africa: Gradual market growth supported by increasing investments and improving economic conditions.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=in-vivo-gene-editing-market

Key Benefits of the Report:

⏩ Comprehensive Market Insights: Gain a deep understanding of market size, trends, and structure.

⏩ Accurate Forecasting: Access reliable future projections to support long-term planning.

⏩ Competitive Analysis: Identify key players, strategies, and positioning in the market.

⏩ Data-Driven Decisions: Make informed business choices backed by verified data.

⏩ Opportunity Identification: Discover emerging trends and untapped growth areas.

⏩ Risk Mitigation: Reduce uncertainties with thorough market evaluation.

⏩ Customer Insights: Understand consumer behavior, preferences, and buying patterns.

⏩ Strategic Planning Support: Align business strategies with market realities.

⏩ Time & Cost Efficiency: Save resources by leveraging ready-to-use research.

⏩ Customization & Expert Validation: Benefit from tailored insights and industry expert analysis.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the In Vivo Gene Editing Market in 2025?
◆ What is the projected growth rate of the In Vivo Gene Editing Market through 2033?
◆ Who are the key players in the In Vivo Gene Editing Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Fabian
Email: fabian@datamintelligence.com
Phone USA: +1 877-441-4866
Phone UK: +44 161-870-5507
Website:https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.